"We'll focus on genomic medicine and growing our business in China"

In May 2023, Cytiva and the life sciences business of Pall Corporation completed their integration and are now united as one business under the Cytiva brand. Emmanuel Ligner, President and CEO, Cytiva and Danaher Group Executive shares some pertinent details with BioSpectrum Asia about the merger, including the strategic rationale behind the decision, the impact on employees, customers, and stakeholders. Ligner reveals the long-term vision and goals for the newly-merged company. Edited excerpts:

- Ayesha Siddiqui

What is the strategic rationale for the merger, and how does it fit into the longterm growth plans of both companies? 

This is a dream come true for three good reasons. First, the life sciences business of Pall and Cytiva complement each other. We listened to our customers who told us they want more complete solutions – from research, to development, and agile manufacturing in new modalities, such as mRNA and cell and gene therapy.

Secondly, the combined manufacturing presence is exciting. We have an incredible opportunity to bring new manufacturing sites in valued spaces around the world, in response to the trend in localisation and regionalisation of manufacturing post-COVID.

Finally, the biotechnology industry is in constant movement and needs a strong collaborator that is capable of creating and innovating tools for transforming bioprocessing. Here, we have an opportunity to develop digital tools that are going to transform bioprocessing. We’ll now have the scale to do this at every phase – from discovery to delivery.

Our combined portfolio and business strengths will better position us for long-term growth. That’s why this integration is transformational and so exciting.

What are the key strengths of both the companies?